Autoimmune Addison's Disease (AAD) is an endocrine and immunological disease of uncertain pathogenesis resulting from the immune system's destruction of the hormone producing cells of the adrenal cortex. The underlying molecular mechanisms are largely unknown, but it is commonly accepted that a combination of genetic susceptibility and environmental impact is critical. In the present study, we identified multiple hypomethylated gene promoter regions in patients with isolated AAD using DNA isolated from CD4+ T cells. The identified differentially methylated regions were distributed evenly across the 10.5-kb-promoter regions covered by the array, and a substantial number localized to promoters of genes involved in immune regulation and autoimmunity. This study reveals a hypomethylated status in CD4+ T cells from AAD patients and indicates differential methylation of promoters of key genes involved in immune responses.
Introduction
Autoimmune disorders constitute a group of diseases that affect 5-10% of the population in western countries and around 3% worldwide (Shapira et al., 2010; Youinou et al., 2010) . Apart from a few autoimmune diseases caused by mutations in single genes (Michels and Gottlieb, 2010) , the etiology of most autoimmune diseases is still unclear. However, it is commonly accepted that a combination of genetic susceptibility and environmental factors are at play, causing breakdown of the natural tolerance mechanisms (Costenbader et al., 2012; Gonzalez et al., 2011; Wing and Sakaguchi, 2010) . The relative importance of environmental factors is illustrated by the facts that monozygotic twins show moderate rates of concordance for autoimmune disorders and that drug-induced autoimmunity is observed after medication with demethylating agents (Javierre et al., 2011) . As the environment directly impacts the epigenetic code, the surrounding milieu of an individual will directly affect gene regulatory mechanisms and disease development.
In autoimmune disorders, the most studied epigenetic mark is DNA methylation, which involves addition of a methyl group to cytosines by DNA methyl transferases (Dnmts). In differentiated mammalian cells >98% of all DNA methylation occurs on cytosines that are followed by guanines (i.e., a CpG site; Jin et al., 2011) . The DNA methylation status of a genomic region will affect the expression of genes, but the outcome will depend on the location of the methylated cytosines. In general, whole genome sequencing studies suggest that hypermethylation of promoter regions is associated with gene silencing, whereas intragenic hypermethylation is linked to gene activation (Aran et al., 2011; Hon et al., 2012) . However, many CpG-rich promoters (i.e., containing CpG islands) are kept demethylated regardless of the transcriptional activity of the corresponding gene (Hawkins et al., 2010) . The DNA methylation signature is changed in many autoimmune diseases, as exemplified by global hypomethylation as well as hypo-or hypermethylation of specific loci (Lu, 2013; Selmi et al., 2012) . Moreover, DNA methylation plays essential roles in normal transcriptional control of key factors in T cell differentiation and function, such as the interferon gamma locus (Sawalha, 2008) , and the transcription factors FoxP3 (forkhead box P3 (Lal et al., 2009 ) and AIRE (Kont et al., 2011) .
Primary adrenal insufficiency (Addison's disease) is a rare disease with a prevalence of around 100-140 per million inhabitants in European countries (Betterle et al., 2002; Laureti et al., 1999; Lovas and Husebye, 2002; Myhre et al., 2002) . The major cause (80-90% of the cases) is an autoimmune reaction toward the adrenal gland, resulting from selective destruction of steroid hormone-secreting cells in the cortex. Autoimmune Addison's disease (AAD) may occur isolated, but in 50% of the cases another autoimmune diseases such as autoimmune thyroid disease and type 1 diabetes (T1D) is present (Eisenbarth and Gottlieb, 2004) . The mechanisms underlying the initiation of the immune-mediated inflammation in AAD remain enigmatic, and as for other autoimmune diseases, it is believed that a combination of genetic and environmental factors affect disease development Selmi et al., 2012) . The vast majority of AAD patients (around 80-90% in different cohorts, (Betterle and Zanchetta, 2003; Erichsen et al., 2009) ) display autoantibodies against the steroidogenic enzyme cytochrome P450 21-hydroxylase (CYP21), but the precise role of this immunoreaction in the pathogenesis of AAD is not well understood. It has been suggested that the destruction of the endocrine cells of the adrenal cortex is mediated by antigen specific CD4+T-helper cells, and executed by cytotoxic T-lymphocytes and macrophages (Bratland and Husebye, 2011) . At the genetic level, several reports from different populations have confirmed a strong link to HLA-DRB*03 and HLA-DRB1*0404. The DRB1*0404 allele is particularly more frequent among AAD patients than other DRB1*04 alleles (Maclaren and Riley, 1986; Skinningsrud et al., 2011; Yu et al., 1999) . As the differences between DRB1*0404 and the other DRB1*04 alleles influence the peptide binding capabilities of HLA molecules, a role of antigenspecific T cell responses in AAD pathogenesis is plausible (Gombos et al., 2007) . The fact that homozygosity for the 5.1 allele of MIC-A gene (located in the HLA complex) increases the probability to develop AAD when present in combination with certain HLA genotypes (Triolo et al., 2009 ) supports a strong role of Human leukocyte antigen (HLA). Outside the HLA complex, polymorphisms in the genes encoding the immunomodulatory factors CTLA4 (cytotoxic T-lymphocyte antigen 4), CIITA (class II, major histocompatibility complex, transactivator), PTPN22 (protein tyrosine phosphatase, non-receptor type 22) and PD-L1 (programmed cell death 1 ligand 1) are commonly found in both AAD and other autoimmune diseases (Blomhoff et al., 2004; Ghaderi et al., 2006; Mitchell et al., 2009; Skinningsrud et al., 2008) . In AAD patients, disease-associated polymorphisms are also frequently found in the genes encoding the vitamin D receptor and NLRP1 (NLR family, pyrin domain containing 1), important for cytokine secretion and inflammatory responses, respectively (Magitta et al., 2009; Pani et al., 2002) . There is no published Genome-wide association study (GWAS) customized for AAD, and at present, we have very limited understanding of the genetic factors that contribute to AAD development at the individual level.
The aim of the present study was to investigate whether DNA methylation abnormalities were linked to AAD. Indeed, a number of differentially methylated regions (DMRs) were identified, the majority of which were hypomethylated in the patients. Moreover, the patients exhibited an overall hypomethylated status. Interestingly, a significant number of the DMRs localized to the promoters of genes encoding factors that are implicated in immune responses and autoimmunity. The results presented in this study might serve as a foundation for future experiments designed to unravel the molecular mechanisms underlying AAD, as well as to generate hypotheses regarding the importance of environment-genome interactions and autoimmunity.
Materials and methods

AAD patients and controls
Peripheral blood was collected in Ethylenediaminetetraacetic acid (EDTA) tubes from patients with isolated AAD and from healthy blood donors. All patients had previously been diagnosed with clinically evident primary adrenocortical insufficiency using standard biochemical measurements (Arlt and Allolio, 2003) . All patients were positive for cytochrome CYP21-antibodies (CYP21-ab) and had been treated with cortisone combined with fludrocortisone since diagnosis (15 ± 14 years). All subjects were females from 20 to 60 year of age (mean 45 ± 13 years and 43 ± 8 years, for cases and controls, respectively). The patients were diagnosed in the age range of 13-54 years (mean age 30 years), and disease duration ranged from 4 to 37 (mean duration 15 years). All patients were born, raised and dwell in Western Norway (Hordaland and Rogaland Counties). All participants signed the informed consent form approved by the Norwegian Health Region West ethics committee (149/96-47.96).
Isolation of CD4+ T cells and DNA
CD4+ T cells were isolated from 12 to 15 ml EDTA blood by the Dynabeads CD4 positive Isolation Kit (Life Technologies/Invitrogen) according to the manufacturer's protocol within 6 h of blood collection. Genomic DNA from CD4+ T cells was extracted using the DNeasy Blood and Tissue Kit (Qiagen) according to the manufacturer's protocol.
Global methylation analyses
The global DNA methylation status was determined on DNA isolated from CD4+ T cells from 16 AAD patients and 16 healthy controls by an ELISA assay (5-mC DNA ELISA kit, Zymo Research, Irvine, CA, USA). Five of these patients and four of the controls contributed to the MeDIP analysis. This kit is based on the recognition and quantification of the methylated DNA fraction using a 5-methylcytosine antibody and a standard curve generated by methylated/demethylated E. coli DNA. The output values were multiplied by the human CpG density/genome factor provided by the manufacturer (according to the manufacturer, the E. coli CpG density/genome length is 0.075 and human CpG density/genome length is 0.009 (28,700,086/3,137,161,264) , and the fold difference between E. coli and human CpG density is 8.3).
MeDIP
Genomic DNA was isolated from nine AAD patients and five healthy control individuals. The DNA was sheared to fragments with an average of 400 bp. Methylated DNA was precipitated using the MagMeDIP kit (Diagnode, Belgium), which is based on magnetic beads and a 5-methylcytidine antibody. The precipitated DNA was purified and eluted from the beads by the IPure kit (Diagnode, Belgium) according to the manufacturer's protocol. To obtain sufficient amount of DNA for microarray hybridization, the immunoprecipitated DNA and input DNA were amplified using the WGA2 kit (Sigma, USA). Amplified products were controlled by qPCR using primer pairs specific for a methylated region (TSH2B) and unmethylated region (GAPDH) according to the manufacturer's protocol.
Array hybridization
The precipitated DNA was hybridized to the NimbleGen Human DNA Methylation 2.1 M Deluxe Promoter Array (NimbleGen-Roche, USA) by Roche NimbleGen Services (Iceland). This array design is based on the HG18 genome build, and covers all transcript and microRNA promoters as well as all 28,226 annotated CpG islands with spacing throughout all tiled regions. Tiling of each transcript promoter begins 7.25 kb upstream of the transcription start site (TSS) and extends downstream 3.25 kb for a total of 10.5 kb of promoter coverage per transcript. Each miRNA promoter (475 total) is tiled from the mature miRNA sequence to 15 kb upstream.
Statistics
Preprocessing and quality control: The raw data included 2,129,040 annotated probes for each of the nine patients and five controls. 2.19% of the probe ids are matched to more than one probe sequence and were excluded from further analysis leading to 2,082,409 probe ids left. After removing probes whose positions have not been localized on the chromosome, the final number for the analysis became 2,000,078 probe ids. We used mediancentered within-array normalization and quantile normalization for between array normalization.
Differentially methylated regions: We performed a t test for each of the 2,000,078 probes and defined the 1% percentile of the nominal p values as to be the threshold for an interesting probe. These interesting probes were then merged into DMR with neighboring probes if the distance to the next interesting probe was less than 500 bp. The region-wise test statistic was defined to be the sum of all (absolute values of the) t test statistics within the DMR. We ended up with 3373 DMRs (Supplementary Table S1 DMRs.xlsx).
Genomic annotation of DMRs
DMRs were associated with TSSs by identifying DMRs whose genomic coordinates intersected with the TSS coordinates. The 10.5 K gene promoter regions were divided into four subregions to further characterize the positions and properties of the identified DMRs (start:end pairs relative to the TSS: −7250/−4625, −4625/−2000, −2000/+625 and +625/+3250). The start coordinate is the first bp in the subregion, and the end coordinate is one past the final bp. Which DMRs overlap with which promoter subregions is presented in Supplementary Table S2 regions overlap.xlsx. If a DMR overlaps with two or more subregions in a promoter region, it is associated with each.
CpG class assignment
Each promoter region or subregion was scanned by sliding a 500-bp window across the region, and calculating the CpG ratio and CG content at each position. CpG ratio was calculated as follows for each 500 bp window: Obs/Exp CpG = N × number of CpG/(number of C × number of G) N: total number of nucleotides. The region is high if there is a 500-bp window where the CpG ratio is > 0.75 and the C + G content is > 0.55. The region is low if there is no window with a CpG ratio > 0.48. The region is intermediate otherwise (Weber et al., 2007) .
Gene ontology and pathway analysis
Gene ontology (GO) analysis was performed using the DAVID Bioinformatics Resource (Huang da et al., 2009 ) with a p value cutoff of 0.05. Pathway analysis and enrichment was done using the KEGG pathway component of the DAVID Bioinformatics Resource. Pathway enrichment was run using the default threshold = 2 and EASE score = 0.1. 
Results and discussion
Global and promoter-specific hypomethylation in patients with AAD
AAD is primarily associated with class II HLA alleles, suggesting that activation of CD4+ T helper cells is a necessity for the disease to develop. CD4+ T cells were therefore used as the source for DNA in further analyses on global DNA methylation and for the identification of potential genomic regions with altered methylation status in AAD patients. By MeDIP combined with array hybridization, we identified 3373 regions that were differentially methylated between AAD patients and controls (Supplementary Table S1 ). The majority of the DMRs were localized in promoter regions, and very few non-promoter CGIs were differentially methylated (i.e., <0.2%). Of the identified DMRs, 89% were hypomethylated in patients compared to controls (Supplementary Data, Table S1 ). Also, as determined by a 5-mC DNA ELISA assay, CD4+ T cell DNA from AAD patients was hypomethylated compared to controls (Fig. 1 ). The observed global methylation level in CD4+ T cell derived from controls is comparable to what has been previously reported (Ziller et al., 2013) , and the relative decrease in methylation in AAD patients is analogous to what has been reported for other autoimmune diseases Javierre et al., 2011; Lei et al., 2009) . A recent comprehensive whole genome bisulfite dataset demonstrates that only around 20% of autosomal CpGs are dynamically regulated with regard to methylation. However, these CpG sites frequently localize to gene regulatory elements, explaining why relatively minor changes in global methylation can have major effects on cell function (Ziller et al., 2013) . Cancer-derived cells are also generally hypomethylated, and whole genome DNA methylation analyses have revealed hypomethylated regions that cluster in the so-called partially methylated domains (PMDs; Hansen et al., 2011; Hon et al., 2012) . PMDs are associated with gene expression hypervariability, presumably as a result of the methylation changes (Hansen et al., 2011; Hon et al., 2012) . It remains to be determined whether a similar organization of hypomethylated regions exists in diseased cells from autoimmune patients. Relative levels of differential methylation levels in hypo-and hypermethylated DMRs calculated as the absolute t statistic value. Students t test, p = 2.7 × 10 −27 (n = 2280 for hypomethylated DMRs, n = 275 for hypermethylated DMRs). The data are presented as mean values ±SE.
As described in Section 2.7, the promoter regions covered by the array were divided into four subregions to further characterize the positions and properties of the identified DMRs. The identified DMRs were distributed uniformly across the four promoter subregions (Supplementary Table S2 ). We categorized the DMRs into high, intermediate, and low CpG content, according to the criteria posted by (Weber et al., 2007 ; see Section 2.8). As expected, based on the documented enrichment of CGIs around TSSs (Deaton and Bird, 2011) , the largest proportion of the DMRs classified as "high" was found in the −2000/+625 promoter regions (Fig. 2a) . The largest proportion of DMRs in all other promoter regions was those DMRs with intermediate CpG content, which might reflect the fact that medium CpG-containing genomic regions are more frequently subjected to differential methylation (Irizarry et al., 2009 ). The relative level of differential methylation (calculated as the absolute t statistic value, Supplementary Data, Table S1) was slightly higher for hypomethylated than for hypermethylated DMRs (Fig. 2b) . The relative differences in methylation did not differ between the different promoter regions, or between regions classified as high, intermediate, or low with regard to CpG content (Supplementary Table  S2 ).
DMRs localize to promoters of genes with essential roles in immunity
A considerable number of the identified DMRs localized to promoters of genes with immunological functions, some of which have already been associated with AAD. The majority of the genes discussed here were differentially methylated in the proximal promoter region (−2000/+625). However, several potentially interesting genes carried abnormal methylation marks in other promoter subregions, demonstrating the importance of examining the whole tiled promoter (Supplementary Table S2 ). As we detected relatively mild differences in MeDIP profiles between patients and controls, these methylation changes could not be validated by bisulfite sequencing (data not shown). In the remaining of Section 3.2, "hypomethylated" and "hypermethylated" refer to that the DMR was hypo or hypermethylated in patients compared to controls.
Hypomethylated DMRs localized to several interferon regulated genes. Among 201 genes recently shown to be upregulated by type I interferons in PBMCs of healthy humans (Waddell et al., 2010) , 13% were differentially methylated in AAD patients compared to controls in our dataset. These included well-described target genes of interferons such as IRF2 (interferon regulatory factor 2), IRF7 (interferon regulatory factor 7), EIF2AK2 (eukaryotic translation initiation factor 2-alpha kinase 2), USP18 (ubiquitin specific peptidase 18), OAS2 (2'-5'-oligoadenylate synthetase 2), and CXCL10 (C-X-C motif chemokine 10/interferon gamma-induced protein 10). A number of these genes are also hypomethylated in naïve CD4+ T cells of patients with SLE, a systemic autoimmune disorder with a strong interferon signature (Coit et al., 2013) . While the type I interferon pathway is considered to play a dominant role in systemic autoimmune disorders, limited data are available on its role in organ-specific autoimmune disorders such as AAD. Yet, IFN␣ is elevated in serum of patients with autoimmune endocrinopathies, including children with newly diagnosed T1D (Chehadeh et al., 2000; Mavragani et al., 2013) . Furthermore, IFN␣ has been suggested as a possible endogenous predisposing factor for adrenal inflammation, as treatment of chronic hepatitis C infection with recombinant IFN␣ induces the level of CYP21-Ab (Wesche et al., 2001) , causes transient primary adrenal insufficiency (Krysiak et al., 2011; Tran et al., 2008) , and worsen clinical features of already existing AAD (Oshimoto et al., 1994) . With regard to CXCL10, it is of interest that several independent studies demonstrate that this chemokine is elevated in sera of AAD patients (Bratland et al., 2013; Ekman et al., 2013; Rotondi et al., 2005) . Considering the identification of DMRs in these gene promoters, it might be hypothesized that the type I interferon pathway is involved in the development of AAD. Whether this represents an epigenetic "poising" of the type I interferon system (as has been described for SLE (Coit et al., 2013) ), or merely a reflection of the ongoing adrenalitis in AAD, remains to be established.
Genes encoding members of the NLRP family of proteins (nucleotide-binding oligomerization domain, leucine-rich repeat and pyrin domain containing; also called NALP) also contained DMRs in their promoter regions. Specifically, NLRP-1, -5, -7, -8, -12, and -13 were found to contain hypomethylated DMRs in their promoter regions in our group of patients. The NLRPs are members of the nucleotide oligomerization domain (NOD)-like receptors (NLRs) that play critical roles in innate immune function (Lupfer and Kanneganti, 2013) . Such functions have been ascribed NLRPs 1 and 12, and the identification of NLRP1 in our dataset is of particular interest since SNPs in this gene have been associated with AAD (Magitta et al., 2009; Zurawek et al., 2010) . However, the DMRs identified here do not overlap with the described SNPs. Upon recognition of microbial ligands or danger-associated molecular patterns NLRP1 forms part of the inflammasome, which cleaves the zymogen pro-caspase 1 into enzymatically active and highly proinflammatory caspase 1 (Franchi et al., 2012) . Intriguingly, another central component of the inflammasome, PYCARD, was also found to be hypomethylated in AAD patients. PYCARD (PYD and CARD domain containing, also known as ASC; apoptosis-associated speck-like protein containing a CARD) is a key adaptor protein that mediates the inflammatory and pro-apoptotic effects of the NLRP1. Once the inflammasome containing NLRP1, PYCARD, and pro-caspase 1 has been established, the proinflammatory cytokines IL1␤ and IL18 are produced from inactive precursors by the activated caspase 1. Interestingly, the genes encoding the receptors for IL1␤, IL1R1 and IL1R2, were also found to contain hypomethylated DMRs. The activated inflammasome has widespread effects, including increased T cell-dependent antibody responses, increased IFN-␥ production by T H 1 cells, and increased rate of differentiation of naïve T cells into T H 17 effector cells (Shaw et al., 2011) . These findings might indicate that NLRP1 and the inflammasome are implicated in the onset or perpetuation of AAD. A similar role for the inflammasome has been suggested for other autoimmune diseases, including RA, vitiligo and T1D (Jin et al., 2007; Kastbom et al., 2008) .
Another striking observation was the high number of hypomethylated DMRs in genes that are often mutated in lymphoid malignancies. These DMRs were located to promoters of genes encoding both chromatin modifiers and histone regulators such as BRCA1 (encoding breast cancer type 1 susceptibility protein), KAT6A/MYST3 (K (Lysine) Acetyltransferase 6A), WHSC1 (probable histone-lysine N-methyltransferase NSD2), DNMT3A (DNA (cytosine-5)-methyltransferase 3A) and BRD3 (bromodomaincontaining protein 3), but also critical components of activating and anti-apoptotic signaling pathways such as CARD11 (caspase recruitment domain-containing protein 11), BIRC5 (baculoviral inhibitor of apoptosis repeat-containing 5/surviving), and MCL1 (induced myeloid leukemia cell differentiation protein; Knoechel and Lohr, 2013) . These findings underline possible converging pathways and mechanisms of autoimmunity and lymphoid neoplasms, both at genetic and epigenetic levels.
Hypomethylated DMRs also mapped to a strikingly high number of genes encoding enzymes of the mitogen-activated protein kinase (MAPK) family. In particular, we identified members of the p38 MAPK pathway, a signaling cascade involved in many autoimmune diseases (Cuenda and Rousseau, 2007) . Also, this pathway is implicated in many processes in CD4+ T cells (Dodeller et al., 2005) , including integration of extracellular signals, T cell activation and differentiation and production of proinflammatory cytokines (Mavropoulos et al., 2013) . Specifically, we found DMRs in the promoter region of the gene encoding MAPK13 (mitogenactivated protein kinase 13, also called p38␦), and in genes upand downstream of MAPK13 in the p38 MAPK signaling cascade: MAP3K4 (encoding MAPK kinase kinase 4), MAP2K6 (encoding MAPK kinase 6), LAT (linker for activation of T cells), and the p38 MAPK substrate ATF2 (activating transcription factor 2). The JNK pathway, another MAPK signaling pathway converging with p38 at ATF2, was also represented among the hypomethylated DMRs. Similar to the p38 MAPK pathway, the JNK signaling cascade is activated by proinflammatory stimuli, but also in response to TcR stimulation (Dong et al., 2002) . Both p38 and JNK pathways are therefore involved in the activation and differentiation of antigenspecific T cells, predominantly of the T H 1 type. It is presumable, therefore, that these pathways are involved in the development of disease-specific IFN␥ producing T cells recognizing CYP21 that have previously been demonstrated in AAD patients (Bratland et al., 2009; Rottembourg et al., 2010) . Hypomethylated DMRs were identified in a considerable number of genes encoding members of the tumor necrosis factor (TNF) superfamily. Among these was TNFRSF1A encoding TNF-R1, the receptor of TNF␣. TNF␣ is a classical proinflammatory cytokine with a demonstrated role in a range of autoimmune diseases such as RA, SLE, multiple sclerosis (MS), and T1D, and also a target for immunotherapeutic intervention in those diseases (Aggarwal, 2003) . Furthermore, we found hypomethylated DMRs in the gene TNFSF14 (encoding lymphotoxin-related inducible ligand that competes for glycoprotein D binding to herpesvirus entry mediator on T cells, or LIGHT). LIGHT is a powerful stimulatory factor for T cells that may contribute to the breach of immunological tolerance in autoimmune diseases (Wang et al., 2001) . Based on the pivotal role played by members of the TNF superfamily in a wide array of autoimmune disorders, we suggest that the findings reported herein indicate a role for the TNF superfamily also in the pathogenesis of AAD.
It is also worth noting that a considerable proportion of the DMRs demonstrating the quantitatively largest methylation difference between patients and controls and the highest number of probe hits, mapped promoters of genes with no previously known roles in the immune response or in autoimmunity; for example, GRIK5 (encoding glutamate receptor, ionotropic, kainite 5) and FBLN1 (encoding fibulin 1). The potential roles for these factors in AAD, if any, are still to be described. Moreover, of interest is also that the promoter region of the gene encoding StAR (steroidogenic acute regulatory protein) was hypomethylated in AAD patients. StAR is essential in steroid hormone biosynthesis as the transporter of cholesterol to the inner mitochondrial membrane (Papadopoulos and Miller, 2012) . Another gene expressed in adrenocortical cells found to be hypomethylated in AAD patients is MC2R (melanocortin receptor 2), the receptor for adrenocorticotropic hormone (ACTH). Whether these findings represent an effect from long-term steroid supplementation in the AAD patients, or rather an intrinsic dysfunction of the adrenal cortex that predisposes for autoimmune adrenalitis remain an open question. CYP21, against which antibodies is the prime known marker for AAD, was not found to be differentially methylated in AAD patients. 
Gene ontology and pathway analyses
We next performed a GO analysis on DMRs localized to the proximal promoter region (2000/+625) as described in Section 2.9. Analyses were carried out for all DMRs (supplementary figure S1), and separately for hypo- (Fig. 3a , see Supplementary Data, Table S3 for list of genes under each GO term) and hypermethylated DMRs (Fig. 3b , see Supplementary Data, Table S4 for list of genes under each GO term). Note that few hypermethylated DMRs were found in the 2000/+625 region (12%; 75/644).
The GO analysis revealed significant enrichment of DMRs within the categories biological processes (BP), molecular function (MF), and cellular compartments (CC). The enrichment of hypomethylated DMRs in the BP-category terms receptor-mediated endocytosis, transport activity, response to stimulus by organic, chemical and endogenous substances and hormone metabolic processes, as well as in the MF-category term transporter activity (Fig. 3a) , probably reflect the combination of steroid hormone supplemental therapy and the lack of endogenous steroid hormone production in the AAD patients. Central genes in several of these BP are present in our dataset. These include APOE (apolipoprotein E), SCAP (sterol regulatory element-binding protein cleavage-activating protein), and ABCG1 (TP-binding cassette subfamily G member 1) that are crucial for regulation of cellular uptake and transmembrane traffic of cholesterol, the precursor of all steroid hormones (Mahley, 1988; Nakajima et al., 1999; Schmitz et al., 2001) . Moreover, genes encoding proteins that are directly interacting with the glucocorticoid receptor and known to modulate the effects of glucocorticoid hormones (e.g., PPARA, encoding peroxisome proliferator-activated receptor alpha and STAT5B, encoding signal transducer and activator of transcription 5B; Bougarne et al., 2009; Wyszomierski et al., 1999) were found to be hypomethylated. It is well established that excessive amounts of endogenous or exogenous glucocorticoids may leave a transient and also stable epigenetic imprints (Khulan and Drake, 2012) . As the AAD patients in this study have taken exogenous glucocorticoids on a daily basis for periods of 4-40 years, an impact on DNA methylation levels was somewhat expected. In fact, several hypomethylated DMRs identified in AAD patients in the present study, localize to genes previously described to be hypomethylated in chronic obstructive pulmonary disease patients treated with systemic steroids (Wan et al., 2012) . These hits include genes encoding proteins with diverse biological functions (e.g., SLC22A18 (solute carrier family 22 member 18), SCNN1A (amiloridesensitive sodium channel subunit alpha), DYRK4 (dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 4), IRF7 (interferon regulatory factor 7), and AIF1 (Allograft inflammatory factor 1, an interferon-␥ inducible Ca 2+ binding EF hand protein). Five related metabolic process terms within the BP-category were significantly enriched for hypomethylated DMRs (Fig. 3a) . These terms, the terpenoid-, diterpenoid-, retinoid-, vitamin A-, and retinoic acid metabolic processes all consisted of the same four genes, namely ALDH1A2 (retinaldehyde dehydrogenase 2), ALDH8A1 (Aldehyde dehydrogenase 8 family, member A1), CYP26C1 (cytochrome P450, family 26, subfamily c, polypeptide 1), and RPE65 (retinal pigment epithelium-specific 65 kDa protein). This is an interesting observation in light of recent discoveries regarding the proinflammatory and immunoregulatory roles of retinoic acid and vitamin A (Hall et al., 2011) .
Within the MF-category, we found enrichment of hypomethylated DMRs in the term exonuclease activity, including genes like APTX (aprataxin) and RAD9 (RAD9), which are both involved in DNA damage control (Niida and Nakanishi, 2006; Sperka et al., 2012; Fig. 3a ). This could be related to the increased extent of genomic DNA damage and killing of lymphocytes by reactive oxygen intermediates in many autoimmune diseases (Bashir et al., 1993) . A second MF-term that showed enrichment of hypomethylated DMRs was serine-type endopeptidase activity, including genes like FURIN (FURIN) and KLK6 (Kallikrein-6; Fig. 3a) . These factors are involved in cleavage of viral proteins and cytokine precursors, and promotion of lymphocyte survival, respectively (Scarisbrick et al., 2011; Tay et al., 2012) . The CC-category revealed significant enrichment of both hypo-and hypermethylated DMRs in genes connected to the cytoskeleton (Fig. 3a and b) , and related terms such as microtubule cytoskeleton and intermediate filaments (Fig. 3b) . We propose that this might reflect the activation and polarization of T cells and lymphocytes that take place in a T cell mediated autoimmune disease such as AAD (Filbert et al., 2012) .
To determine the potential enrichment of pathways in our dataset, we used the KEGG functional annotation tool in DAVID (as described in Section 2.9). Although a substantial number of the genes containing hypomethylated DMRs in their proximal promoter regions are involved in immunological pathways, none of these pathways were enriched. The only significantly enriched pathways were found for hypermethylated DMRs and included melanogenesis and axon guidance (Table 1 ). Since the number of genes with hypermethylated DMRs in each pathway was only three, and since the p values approached the borderline of significance, this finding should be interpreted with caution. However, the enrichment of hits within the melanogenesis pathway is noteworthy since one of the cardinal signs of AAD is hyperpigmentation of the skin due to excessive production of ACTH (Bratland and Husebye, 2011) .
In the present study, we utilized DNA isolated from CD4+ T cells as the starting material to identify DMRs. This pool consists of different subpopulations of cells, and in the body, the relative abundance of each subtype will depend on various signals present in their milieu. In fact, the distribution of CD4+ T cell subtypes is frequently altered in autoimmune diseases (Buckner, 2010) . In AAD, an increased percentage of activated T cells is observed in patients with recent onset of disease, and moreover, a decreased percentage of suppressive T REGS is evident (Coles et al., 2005; Rabinowe et al., 1984) . This characteristic of autoimmune diseases, together with the fact that the DNA methylome differs between CD4+ T subtypes (Lee et al., 2009 ) can potentially confound our results. For example, in our dataset, DMRs were localized to the promoter regions of LIF (leukemia inhibitory factor), PIAS3 (E3 SUMO-protein ligase PIAS3), and RORC (retinoic acid receptor (RAR)-related orphan receptor C). It has previously been demonstrated that these genes can be regulated by methylation, and moreover these genes are differentially expressed in CD4+ T cell populations (Bixler et al., 2013; Cao et al., 2011; Kluge et al., 2011; Mycko et al., 2012; Santarlasci et al., 2012; Shin et al., 2011; Thomas et al., 2012) . Although the limited number of cells hampered experiments on individual CD4+ T cell subpopulations at this time, such experiments should be possible in the coming years as the DNA methylation techniques advance and allow satisfactory analyses on few cells. It is already possible to separate most known subpopulations based on cell-specific markers (Bendall et al., 2011) . Another limitation is that the assay does not provide information about whether the identified DMRs are causes or consequences of the disease. Moreover, as indicated by the GO-analyses (discussed in Section 3.3), it is possible that the abnormal methylation pattern in AAD patients has developed partly as a result of medication. However, such changes are also valuable to monitor as they may hint to genomic regions and cellular pathways that are important to take into account for upcoming proposals for improved patient treatment and care. Future studies should be designed to determine when and where differences in methylation status arise. Important tools for such analyses will be cohorts of individuals that have not yet developed AAD, but have CYP21-Ab, and animal models that allow cell tracking in combination with DNA methylation analyses. 
Conclusion
Dysregulation of epigenetic processes is an essential contributing factor in the development of autoimmune diseases, underscoring the importance in identifying and mapping epigenetic alterations in patients. Our results suggest that a number of genes involved in immune regulation and autoimmunity carry abnormal DNA methylation signatures in a cohort of AAD patients. It remains to be determined whether these epigenetic changes has arisen as a consequence of the disease and/or medical treatment, or whether they are contributing to disease development. Nevertheless, this report can serve as a foundation to reveal the molecular mechanisms underlying AAD.
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